Results 1 to 10 of about 34,696 (251)

Radiopharmaceuticals

Nature Biotechnology
The purpose of this Special Issue was to host research and review papers on Radiopharmaceuticals in line with the three previous Special Issues that I have Guest Edited for Molecules.
Singh C, Heston TF.
europepmc   +4 more sources

Future Prospective of Radiopharmaceuticals from Natural Compounds Using Iodine Radioisotopes as Theranostic Agents

Molecules, 2022
Natural compounds provide precursors with various pharmacological activities and play an important role in discovering new chemical entities, including radiopharmaceuticals.
Isti Daruwati, Amirah Mohd Gazzali, Toto Subroto   +2 more
exaly   +3 more sources

Therapy with Radiopharmaceuticals [PDF]

Acta Oncologica, 2002
In an investigation by the Swedish Cancer Society, an expert group described the present status, critical issues and future aspects and potentials for each of nine major areas of radiation therapy research. The present report deals with therapy with radiopharmaceuticals.
Jörgen, Carlsson, Eva, Forssell-Aronsson, Bengt, Glimelius, Sören, Mattsson, The, Swedish Cancer Society Investigation Group   +4 more
core   +4 more sources

Preparation and evaluation of [64Cu]Cu-labeled bisphosphonate amide of DOTA using reactor-produced 64Cu as an affordable skeletal PET imaging agent [PDF]

Scientific Reports
Non-invasive imaging of skeletal metastases by Positron Emission Tomography (PET) for cancer prognosis, staging and treatment monitoring is one of the prominent fields of radiopharmaceutical research.
Priyalata S. S. Shetty, K. V. Vimalnath, Sourav Patra, Sutapa Rakhit, Avik Chakraborty, Sudipta Chakraborty   +5 more
doaj   +2 more sources

Synthesis and comparative evaluation of 177Lu-labeled PEG and non-PEG variant peptides as HER2-targeting probes

Scientific Reports, 2022
Highest global cancer incidence of female breast cancer is a matter of great concern. HER2-positive breast cancers have high mortality rate hence detection at an early stage is vital for successful treatment, improved cancer care and survival rate ...
Amit Kumar Sharma, Rohit Sharma, Kusum Vats, Haladhar Dev Sarma, Archana Mukherjee, Tapas Das, Drishty Satpati   +6 more
doaj   +1 more source

Comparison of regional flortaucipir PET with quantitative tau immunohistochemistry in three subjects with Alzheimer’s disease pathology: a clinicopathological study

EJNMMI Research, 2020
Background The objective of this study was to make a quantitative comparison of flortaucipir PET retention with pathological tau and β-amyloid across a range of brain regions at autopsy.
Michael J. Pontecorvo, C. Dirk Keene, Thomas G. Beach, Thomas J. Montine, Anupa K. Arora, Michael D. Devous, Michael Navitsky, Ian Kennedy, Abhinay D. Joshi, Ming Lu, Geidy E. Serrano, Lucia I. Sue, Anthony J. Intorcia, Shannon E. Rose, Angela Wilson, Leanne Hellstern, Natalie Coleman, Matthew Flitter, Patricia Aldea, Adam S. Fleisher, Mark A. Mintun, Andrew Siderowf   +21 more
doaj   +1 more source

Fast Fluorine-18 labeling and preclinical evaluation of novel Mucin1 and its Folate hybrid peptide conjugate for targeting breast carcinoma

EJNMMI Radiopharmacy and Chemistry, 2021
Background There is a need to develop new and more potent radiofluorinated peptide and their hybrid conjugates for multiple-receptors targeting properties that overexpress on many cancers.
I. Al Jammaz, B. Al-Otaibi, Y. Al-Malki, A. Abousekhrah, S. M. Okarvi   +4 more
doaj   +1 more source

Preparation and Preliminary Imaging of Novel Albumin-Binding PSMA Ligand ［177Lu］Lu-DOTA-CPN-PSMA

He huaxue yu fangshe huaxue, 2023
A novel PSMA targeting molecule ［177Lu］Lu-DOTA-CPN-PSMA with high uptake and long retention in prostate cancer was developed, in which DOTA was used as the bifunctional chelator, glutamic acid-urea-lysine(Glu-Urea-Lys) was used as the targeting group ...
LUO Tian-wei, SUN Ming-yue, ZHANG Wen-hui, GAO Fei, WANG Ning, HUANG Xu-hu, CHEN Huan, LI Hong-yu   +7 more
doaj   +1 more source

Electrochemical separation and purification of no-carrier-added 177Lu for radiopharmaceutical preparation: Translation from bench to bed

Chemical Engineering Journal Advances, 2023
The entry of no-carrier-added (NCA) 177Lu in the arena of clinical nuclear medicine has revolutionized the practice of targeted radionuclide tumor therapy.
Sourav Patra, Rubel Chakravarty, Khajan Singh, K.V. Vimalnath, Sudipta Chakraborty   +4 more
doaj   +1 more source

Preparation and Bioevaluation of a Novel ^99mTc-Labeled Glucose Derivative Containing Cyclohexane as a Promising Tumor Imaging Agent

Pharmaceuticals, 2023
To develop novel tumor imaging agents with high tumor uptake and excellent tumor/non-target ratios, a glucose derivative containing cyclohexane (CNMCHDG) was synthesized and labeled with Tc-99m.
Junhong Feng, Xuran Zhang, Yuhao Jiang, Qing Ruan, Qianna Wang, Junbo Zhang   +5 more
doaj   +1 more source